GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca PLC (NAS:AZN) » Definitions » Debt-to-Equity

AZN (AstraZeneca) Debt-to-Equity : 0.85 (As of Jun. 2024)


View and export this data going back to 1993. Start your Free Trial

What is AstraZeneca Debt-to-Equity?

AstraZeneca's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $5,359 Mil. AstraZeneca's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $28,174 Mil. AstraZeneca's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $39,512 Mil. AstraZeneca's debt to equity for the quarter that ended in Jun. 2024 was 0.85.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for AstraZeneca's Debt-to-Equity or its related term are showing as below:

AZN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.49   Med: 1.16   Max: 2.06
Current: 0.85

During the past 13 years, the highest Debt-to-Equity Ratio of AstraZeneca was 2.06. The lowest was 0.49. And the median was 1.16.

AZN's Debt-to-Equity is ranked worse than
81.33% of 825 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs AZN: 0.85

AstraZeneca Debt-to-Equity Historical Data

The historical data trend for AstraZeneca's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Debt-to-Equity Chart

AstraZeneca Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.39 1.31 0.78 0.79 0.73

AstraZeneca Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.77 0.73 0.92 0.85

Competitive Comparison of AstraZeneca's Debt-to-Equity

For the Drug Manufacturers - General subindustry, AstraZeneca's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Debt-to-Equity falls into.



AstraZeneca Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

AstraZeneca's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

AstraZeneca's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AstraZeneca  (NAS:AZN) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


AstraZeneca Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of AstraZeneca's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


AstraZeneca Business Description

Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

AstraZeneca Headlines

From GuruFocus

Q1 2024 AstraZeneca PLC Earnings Call Transcript

By GuruFocus Research 04-26-2024